Boey® (trenibotulinumtoxinE), developed by Allergan Aesthetics, received a positive opinion from the European Medicines Agency's CHMP for approval in 30 EU and EEA countries to temporarily improve moderate to severe glabellar lines in adults. Supported by two Phase 3 trials, Boey® showed rapid effects within 8 hours and lasted 2-3 weeks with a safety profile similar to placebo. If approved by the European Commission, Allergan plans to train healthcare professionals and launch the product commercially soon. This could be the first botulinum toxin serotype E treatment available for facial lines, addressing a significant psychological concern for many patients.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
